Longitudinal Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Background: Hereditary hematopoietic malignancy (HHM) syndromes are a group of inherited disorders that raises the risk of blood cancers. Many people with HHMs have changes in a gene (DDX41) that makes it more likely that they will develop myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or other cancers. This natural history study will explore the link between HHM syndromes and these diseases.

Objective: To study the link between HHM and MDS/AML.

Eligibility: People aged 1 month and older with HHM. Relatives with HHM are also needed.

Design: Participants aged 3 years and older will have 1 initial clinic visit with the option to follow-up annually. They will undergo these procedures: They will have a physical exam with blood and urine tests. They may give samples of saliva, stool, nails, and skin. Their ability to do normal activities will be reviewed. Some may have a bone marrow biopsy: A tissue sample will be drawn from inside a bone. They may answer questions about their health and family medical history. Participants younger than 3 years, and those who cannot come to the clinic, will be contacted by phone or email. Their samples may be collected locally and sent to researchers. For participants who have changes in their DDX41 gene: Researchers will contact them or their primary care provider once a year for 10 years. Researchers will check on participants health and collect any new test results. Some may be asked to send new samples. Participants who do not have changes in their DDX41 gene may be contacted yearly, or less often, for 10 years. Some participants may be asked to return to the clinic if needed.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 1 month
Maximum Age: 120
Healthy Volunteers: f
View:

• Age \> 1 month old.

• Participants with history of aberrations that affect the DDX41 gene, DDX41 RNA, or DDX41 protein (Cohorts 1-2)

⁃ OR

⁃ Participants with history of aberrations in another HHM variant (Cohort 3)

⁃ OR

⁃ Participants with history of absence of HHM variants, who have first or second degree relative with history of confirmed or suspected HHM variant(s) per participant report (Cohort 4).

• Participants must have an identified healthcare provider outside of NIH who manages participant care, and any diagnostic clinical findings provided by this study.

• Ability of participant or parent/guardian to understand and the willingness to sign a written consent document.

Locations
United States
Maryland
National Institutes of Health Clinical Center
RECRUITING
Bethesda
Contact Information
Primary
Rebecca B Alexander
rebecca.alexander@nih.gov
(240) 781-4037
Backup
Sung-Yun Pai, M.D.
sung-yun.pai@nih.gov
(240) 858-7284
Time Frame
Start Date: 2025-07-24
Estimated Completion Date: 2035-06-15
Participants
Target number of participants: 510
Treatments
Cohort 1
Participants with confirmed aberrations that affect the DDX41 gene, DDX41 RNA, or DDX41 protein and who have a history of MDS/MPN/AML diagnosis
Cohort 2
Participants with confirmed aberrations that affect the DDX41 gene, DDX41 RNA, or DDX41 protein and who do NOT have history of MDS/MPN/AML
Cohort 3
Participants with confirmed aberrations in another HHM variant
Cohort 4
Participants with confirmed absence of known HHM variants, and who have first or second degree relative with confirmed or suspected HHM variant(s) (control group)
Sponsors
Leads: National Cancer Institute (NCI)

This content was sourced from clinicaltrials.gov

Similar Clinical Trials